



October 28, 2020

Re: SECURE-IBD COVID-19 update #18


Dear Colleagues,

We hope this newsletter finds you safe and well as we are sadly starting to experience a second wave of COVID-19 in many countries. As of October 27, 2020, there have been 2,797 COVID-19 cases in IBD patients reported in SECURE-IBD, paralleling this rise in COVID-19.

We are accepting applications to share de-identified SECURE-IBD data with qualified investigators until Monday, November 2, 2020. Please share this information with interested colleagues, trainees and especially students. We plan to open a second round of applications subsequently. In other exciting news, [our paper](#) on the effect of IBD medications on COVID-19 outcomes is now published in Gut. This updated analysis of nearly 1,500 patients from SECURE-IBD observed that thiopurine monotherapy and combination therapy are associated with an increase in severe COVID-19 outcomes compared to anti-TNF monotherapy. In addition, further data on mesalamine and other biologic classes are reviewed. [Our analysis](#) of 209 children with IBD and COVID-19, in collaboration with the pediatric Porto group registry in Europe, is published in CGH. Consistent with data in the general population, most pediatric IBD patients had a mild course of COVID-19.

A few other reports from SECURE-IBD are also in the pipeline.

Please continue to spread the word about SECURE-IBD to all of your colleagues, locally, nationally, and internationally!



Interactive web-based map: <http://covidibd.org/map/>

You may download flyers translated into 17 languages at <https://covidibd.org/press/>

Frequently Asked Questions

What is SECURE-IBD? Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE-IBD) is an international, pediatric and adult registry to monitor and report on outcomes of COVID-19 occurring in IBD patients. The registry contains only de-identified data, in accordance with [HIPAA Safe Harbor De-Identification standards](#). The UNC-Chapel Hill Office for Human Research Ethics has determined that storage and analysis of de-identified data does not

constitute human subjects research as defined under federal regulations [45 CFR 46.102 and 21 CFR 56.102] and does not require IRB approval.

How can a provider report a case? We encourage **all IBD providers to report all cases of confirmed COVID-19** in IBD patients, regardless of severity. Reporting should take at most 5 minutes. Please report only confirmed COVID-19 cases, and report after a minimum of 7 days from COVID diagnosis and sufficient time has passed to observe the disease course through resolution of acute illness or death. **To report a case of coronavirus, click [here](#)**

Who is organizing this project? This project is being led by Drs. Michael Kappelman (Pediatric Gastroenterologist) and Erica Brenner (Pediatric Gastroenterology fellow) at the University of North Carolina at Chapel Hill and Dr. Ryan Ungaro (Gastroenterologist), Dr. Manasi Agrawal (Gastroenterologist) and Dr. Jean-Frederic Colombel (Gastroenterologist) at the Icahn School of Medicine at Mount Sinai, New York.

Are there any partnering organizations/societies? Official partners include the Crohn's & Colitis Foundation, the International Organization for the Study of IBD (IOIBD), the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN), the European Crohn's and Colitis Organisation (ECCO), the Asian Organization for Crohn's & Colitis, and the Pan American Crohn's and Colitis Organisation (PANCCO). We also acknowledge the promotional support of many local/regional societies and pharmaceutical companies as detailed on www.covidibd.org.



European
Crohn's and Colitis
Organisation



Please visit us at www.covidibd.org for updated information or to report a case.

Follow us on Twitter: @SecureIBD

If you have any questions, please reach out to COVID.IBD@unc.edu.

Through worldwide collaboration, we can make a large difference!

Best,

Mike, Erica, Jean-Fred and Ryan and Manasi

Advisory Committee Members

North America: Jim Lewis and Gil Kaplan

Nursing and Advanced Practitioners: Michele Kissous-Hunt

Europe: Walter Reinisch and Jean-Francois Rahier

Asia: Siew Ng

S. America: Flavio Steinwurz

Australia/New Zealand: Richard Gearry

Industry: Irene Modesto

IOIBD: Marischka Konings